Heart failure & cardiomyopathies
The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset
Authors' conclusion
Rigorous confounding adjustment suggests polypharmacy is associated with mortality following hospitalisation for HFrEF but not HFpEF.
Study context
- Population
- Patients with first HF hospitalisation (PULSE dataset)338 died
- Participants
- 660 patients
- Exposure
- Hyperpolypharmacy vs polypharmacy at discharge
- Outcome
- Mortality
- Follow-up
- Median 2.9 years
Methodological detailslongitudinal, inverse probability weighting
- Longitudinal
- Inverse probability weighting
Main finding
As reported in the abstract
Mortality, hyperpolypharmacy vs polypharmacy (heart failure with reduced ejection fraction (HFrEF)) · end of follow-up
Hyperpolypharmacy vs PolypharmacyHazard ratio (CI)P value
Univariable
1.95(1.36–2.82)
P < 0.001- 26% higher mortality; inverse probability weighting
- average treatment effect (Coeff.) −0.26 (CI −0.43 to −0.09); P = 0.003
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| Mortality, hyperpolypharmacy vs polypharmacy (HFpEF) · end of follow-upHyperpolypharmacyvs PolypharmacyUnivariable | 0.93 (0.70–1.24) | P = 0.63 | |
| Mortality, HFpEFvs HFrEF32% higher mortality | 1.32 (1.08–1.61) | P = 0.007 | |
| 0.512Hazard ratio (log scale) |
| Outcome | Average treatment effect (Coeff.) (CI) | P value |
|---|---|---|
| Mortality, hyperpolypharmacy vs polypharmacy (HFpEF) · end of follow-upHyperpolypharmacy vs Polypharmacy | −0.03 (−0.15 to 0.08) | P = 0.55 |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset. ESC Heart Fail. Published 11 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →